Catalent (CTLT)
(Delayed Data from NYSE)
$55.80 USD
-0.01 (-0.02%)
Updated May 13, 2024 04:00 PM ET
After-Market: $55.80 0.00 (0.00%) 5:12 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.80 USD
-0.01 (-0.02%)
Updated May 13, 2024 04:00 PM ET
After-Market: $55.80 0.00 (0.00%) 5:12 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.
Here's Why Catalent (CTLT) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalent's (CTLT) New Project Completion Expands Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent's (CTLT) New Tie-Up to Provide Better Patient Access
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.
Catalent (CTLT) Down 3.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.
Catalent (CTLT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.
Catalent (CTLT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.
BD (BDX) Hits a New 52-Week High: What's Behind the Rally?
by Zacks Equity Research
A slew of strategic acquisitions are driving the top line for BD (BDX).
Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP
by Zacks Equity Research
Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent (CTLT) to Advance Oral Drug Development With New Launch
by Zacks Equity Research
Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.
PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues
by Zacks Equity Research
PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
AMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances.
Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid
by Zacks Equity Research
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.